$PHAT News

Phathom Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript

Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

Phathom Pharmaceuticals (PHAT) Falls After Cutting 2026 Revenue Guidance Despite Q2 Beat

Phathom Pharmaceuticals Q2 Adj. EPS $0.00 Beats $(0.25) Estimate, Sales $74.300M Beat $72.789M Estimate

Phathom Pharmaceuticals Lowers FY2026 Sales Guidance from $320.000M-$345.000M to $310.000M-$325.000M vs $332.196M Est

Phathom Pharmaceuticals Q2 Sales $74.300M Beat $72.789M Estimate

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom Pharmaceuticals Completes Patient Enrollment In Its Phase 2 pHalcon-EoE-201 Clinical Study Of VOQUEZNA Tablets To Treat Eosinophilic Esophagitis In Adults

HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Phathom: Why I'm Downgrading To "Sell" Ahead Of Competition

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline

How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

Phathom Pharmaceuticals Q1 Earnings Call Highlights